Healthcare / Drug Manufacturers - Specialty & GenericNSE
$720.00
-18.10 (-2.40%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $2.9B · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$141.5B
P/E
21.0x
↑EV/EBITDA
13.9x
↑ROE
11.9%
↑Gross Margin
73.0%
↑Debt/Equity
0.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+10.1%
FCF CAGR
+0.9%
FCF margin
3.9%
FCF / Net income
0.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $73.45B · net income $6.75B · FCF $2.88B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $73.45B | $73.45B | $66.72B | $61.12B | $55.00B |
| Net Income | $6.75B | $6.75B | $5.83B | $6.16B | $3.42B |
| EBITDA | $11.06B | $11.06B | $10.65B | $9.61B | $6.80B |
| EPS | 34.33 | 34.33 | 29.68 | 31.33 | 17.40 |
| Gross Margin | 73.0% | 73.0% | 73.1% | 67.3% | 63.2% |
| Operating Margin | 10.9% | 10.9% | 10.9% | 10.9% | 8.1% |
| Net Margin | 9.2% | 9.2% | 8.7% | 10.1% | 6.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.25 | 0.25 | 0.24 | 0.11 | 0.17 |
| Current Ratio | 1.76 | 1.76 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $2.88B | $2.88B | $-4.76B | $4.76B | $2.81B |
| Returns | |||||
| ROE | 11.9% | 11.9% | 11.2% | 12.8% | 7.8% |
| Valuation | |||||
| P/E | 20.99 | 20.99 | 29.69 | 32.19 | 29.22 |
| EV/EBITDA | 13.91 | 13.91 | 17.38 | 21.04 | 15.65 |
| P/B | 2.49 | 2.49 | 3.34 | 4.11 | 2.29 |
| Growth & Yield | |||||
| Revenue Growth | 10.1% | 10.1% | 9.2% | 11.1% | — |
| EPS Growth | 15.7% | 15.7% | -5.3% | 80.1% | — |
| Dividend Yield | 1.5% | 1.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
23.0%
EPS terminal req.
$63.89
Spread vs growth
-7.3%
5Y implied EPS CAGR
17.6%
EPS terminal req.
$77.30
Spread vs growth
-2.0%
10Y implied EPS CAGR
13.7%
EPS terminal req.
$124.50
Spread vs growth
1.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.1%
Start / end P/E
33.3x → 21.4x
EPS bridge
29.68 → 34.33
Residual
-5.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.